Abstract
The safety and efficacy of a new potent longlasting opioid antagonist, nalmefene (6-desoxy-6-methylene-naltrexone), were evaluated in this open label study. The ability of malmefene to reverse the effects of morphine in 30 women who underwent voluntary tubal ligation with 0.2-0.5 mg/kg of morphine, i.m., as premedication was determined. Efficacy of nalmefene was assessed by measuring alertness (reversal of narcosis) and increase in pain (reversal of analgesia). Both measures of efficacy were significantly increased within 30 minutes of nalmefene administration (p < 0.05). Heart rate, respiratory rate, and blood pressure were not affected, suggesting acceptable tolerance.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 25-29 |
| Number of pages | 5 |
| Journal | Journal of Clinical Research and Drug Development |
| Volume | 7 |
| Issue number | 1 |
| State | Published - Jan 1 1993 |
| Externally published | Yes |
Keywords
- Analgesia
- Nalmefene
- Narcosis
- Opioid antagonist
- Tubal ligation
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology (medical)